Use of Bacteroides fragilis in the prevention and/or treatment of meningitis

A technology of Bacteroides fragilis and meningitis, applied in the field of application of Bacteroides fragilis in the prevention and/or treatment of meningitis, to achieve broad application prospects and the effect of not producing drug resistance

Active Publication Date: 2019-11-08
石家庄普维生物科技有限公司
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the use of B. fragilis to treat meningitis has not been documented in the literature

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of Bacteroides fragilis in the prevention and/or treatment of meningitis
  • Use of Bacteroides fragilis in the prevention and/or treatment of meningitis
  • Use of Bacteroides fragilis in the prevention and/or treatment of meningitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Isolation and Purification of Bacteroides fragilis ZY-312

[0048] Reagents and Instruments

[0049] (1) Medium A: Bacteroides-bile-escin (BBE) agar (Qingdao Haibo Biotechnology Co., Ltd., product number: HB7028) was added with an improved formula, and the specific components are shown in Table 1:

[0050] Table I

[0051]

[0052]

[0053] (2) Medium B: Bacteroides-bile-escin (BBE) agar (Qingdao Haibo Biotechnology Co., Ltd., product number: HB7028) was added with an improved formula, and the specific ingredients are as follows in Table 2:

[0054] Table II

[0055]

[0056] (3) Medium C: Fetal bovine serum was added to Brinell Broth (Qingdao Haibo Biotechnology Co., Ltd., product number: HB0241), and the addition amount was 5% (v / v) (Zhejiang Tianhang Biotechnology Co., Ltd., Brand: Sijiqing, Item No.: HB0205).

[0057] (4) Experimental equipment

[0058] 2.5L sealed culture tank (Mitsubishi Gas Chemical Co., Ltd., C-31)

[0059] Constant temperature in...

Embodiment 2

[0097] Identification of Bacteroides fragilis ZY-312

[0098] The polymerase chain reaction (PCR) primer (synthesized by Yingwei Jieji (Shanghai) Trading Co., Ltd.) sequence is as follows:

[0099] Primer pair 1:

[0100] Forward primer: 5'-ACGCTTGCACCCCTCCGTATTA-3'

[0101] Reverse primer: 5'-GCTTAGAGTTTGATCCTGGCTCAG-3'

[0102] Primer pair 2:

[0103] Forward primer: 5'-TGGGTGGTTGCTGCCTGGACACA-3'

[0104] Reverse primer: 5'-CATCCGGGTATGGATATGAA-3'

[0105] Primer pair 3:

[0106] Forward primer: 5'-GATGCTCCAGTTACAGCTTCCATTG-3'

[0107] Reverse primer: 5'-CGCCCAGTATATGACCTAGTTCGTG-3'

[0108] bft gene primer pair:

[0109] Forward primer: 5'-GACGGTGTATGTGATTTGTCTGAGAGA-3'

[0110] Reverse primer: 5'-ATCCCTAAGATTTATTATCCCAAGTA-3'

[0111] 1. PCR identification (PCR is the polymerase chain reaction, which is a commonly used method for rapidly amplifying genes)

[0112] (1) 16S rRNA sequence determination

[0113] The above strains were inoculated on medium A, and cu...

Embodiment 3

[0134] Tolerance of Bacteroides fragilis ZY-312 to Gastric Acid

[0135] 1. Artificial gastric juice preparation (according to the 2010 "Chinese Pharmacopoeia" artificial gastric juice preparation method)

[0136] Dissolve 23.4mL of concentrated HCl in 100mL of purified water to obtain dilute hydrochloric acid. Take 8.2mL dilute hydrochloric acid, add 400mL purified water and 5g pepsin ( Porcine source, 1:15000), dilute to 500mL. Stir overnight at 37°C with magnetic force to obtain artificial gastric juice.

[0137] 2. Cell preparation

[0138] Collect the bacterial solution, centrifuge, discard the supernatant, resuspend in normal saline, centrifuge again, discard the supernatant, and keep the bacteria for later use.

[0139] 3. Add artificial gastric juice to determine the number of viable bacteria

[0140] Add artificial gastric juice to the bacteria, resuspend, and measure the number of viable bacteria at 0, 1, 2, and 3 hours respectively.

[0141] The 10-fold seria...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The application of Bacteroides fragilis in the prevention and / or treatment of meningitis, specifically relates to the application of Bacteroides fragilis in the preparation of medicines, pharmaceutical compositions, food, health products and food additives for the prevention and / or treatment of meningitis, wherein , said Bacteroides fragilis is Bacteroides fragilis ZY‑312, which was deposited in China General Microorganism Culture Collection and Management Center on April 2, 2015, and its preservation number is CGMCC No.10685. The Bacteroides fragilis of the present invention has a good effect on the prevention and / or treatment of meningitis, does not produce drug resistance, is safe and non-toxic, does not contain enterotoxin gene bft, and has bile salt resistance, It has probiotic properties such as gastric acid resistance and has broad application prospects.

Description

technical field [0001] The invention relates to the technical fields of microorganisms, medicines, health care products, food and daily chemical products, in particular to the application of Bacteroides fragilis in the prevention and / or treatment of meningitis. Background technique [0002] Bacterial meningitis is a serious infectious disease of the central nervous system, common in adults, but the most common in neonates. Neonates are high-risk groups for bacterial meningitis because of their low immune function, imperfect leukocyte chemotaxis, adhesion and migration, complement activity, and low concentrations of specific and non-specific antibodies in the body. [0003] In the 1930s, the advent of sulfa drugs reduced the fatality rate of spherical meningitis to 5%-15%. By 1944, 87 children with Haemophilus influenzae type b meningitis were treated with sulfonamides and intravenous rabbit antiserum, reducing the fatality rate to 22%. In the early 1960s, chloramphenicol (...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12N1/20C12R1/01
CPCA61K35/74C12N1/20C12N1/205C12R2001/01
Inventor 智发朝白杨王晔刘洋洋王从峰
Owner 石家庄普维生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap